Lunai Bioworks (LNAI) Other Accumulated Expenses (2020 - 2026)
Lunai Bioworks (LNAI) posted quarterly Other Accumulated Expenses of $364632.0 for Q1 2026, down 33.25% year-over-year from $546265.0 in Q1 2025, and up 390.46% quarter-over-quarter from $74345.0 in Q4 2025.
Lunai Bioworks (LNAI) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Lunai Bioworks' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $364632.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 33.25% year-over-year to $364632.0; the TTM figure through Mar 2026 stood at $364632.0 (down 33.25% YoY), while the FY2025 annual figure was $378282.0, up 28.07% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $364632.0, up from $74345.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $875415.0 in Q4 2022, with the low at $12030.0 in Q1 2022.
- The 5-year median for Other Accumulated Expenses is $329996.5 (2024), against an average of $354326.6.
- The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses soared 4064.99% in 2023, then slumped 90.91% in 2025.
- Lunai Bioworks' Other Accumulated Expenses stood at $875415.0 in 2022, then declined by 23.54% to $669384.0 in 2023, then climbed by 22.19% to $817908.0 in 2024, then plunged by 90.91% to $74345.0 in 2025, then jumped by 390.46% to $364632.0 in 2026.
- Business Quant data shows LNAI's Other Accumulated Expenses at $364632.0 in Q1 2026, $74345.0 in Q4 2025, and $71429.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 364,632.00 |
| Dec 31, 2025 | 74,345.00 |
| Sep 30, 2025 | 71,429.00 |
| Jun 30, 2025 | 378,282.00 |
| Mar 31, 2025 | 546,265.00 |
| Dec 31, 2024 | 817,908.00 |
| Sep 30, 2024 | 102,741.00 |
| Jun 30, 2024 | 295,361.00 |
| Mar 31, 2024 | 519,427.00 |
| Dec 31, 2023 | 669,384.00 |
| Jun 30, 2023 | 184,733.00 |
| Mar 31, 2023 | 501,048.00 |
| Dec 31, 2022 | 875,415.00 |
| Sep 30, 2022 | 35,540.00 |
| Jun 30, 2022 | 220,685.00 |
| Mar 31, 2022 | 12,030.00 |
| Dec 31, 2021 | 24,181.00 |
| Sep 30, 2021 | 6,000.00 |
| Jun 30, 2021 | 90,602.00 |
| Mar 31, 2021 | 6,000.00 |